

Closing the COVID-19 Test to Treatment Gap Webinar

February 24, 2022

Access speaker bios here: <u>https://files.asprtracie.hhs.gov/documents/aspr-test-</u> <u>to-treatment-gap-webinar-bios.pdf</u> Access the recording here: <u>https://attendee.gotowebinar.com/</u> recording/3795092347924826383



Welcome/Opening Remarks

Shayne Brannman, MS, MA Director, ASPR TRACIE

Disclaimer

The views, opinions, and/or findings expressed are those of the author and should not be interpreted as representing the official views or policies of the U.S. Department of Health and Human Services or the U.S. Government.


ASPR Key Priorities

To meet the nation's health/medical needs, ASPR is focused on three key priorities: Extend capabilities to respond well and emerge quickly from the COVID-19 pandemic

Restore resources and capabilities diminished during the pandemic

Prepare for future emergencies whether natural or man-made

ASPR TRACIE: Three Domains



Introductions

Cicely Waters, MS Moderator

Director, Office of External Affairs Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human services




Objectives & Setting the Stage

- Throughout COVID-19 response, federal government steadfast in supporting health care community
- Environment remains dynamic
- Landscape of medical countermeasures has evolved
- Provide overview of COVID-19 therapeutics landscape
- Highlight initiatives to help close Test to Treatment gap
- Discussion
- Q/A

Derek Eisnor, MD

Medical Officer, Division of Clinical Development, Biomedical/Advanced Research and Development Authority (BARDA) COVID-19 Allocation and Distribution Lead, HHS ASPR

Summary of COVID-19 Preventative Agents & Therapeutics



¹ <u>NIH COVID-19 Treatment Guidelines</u> https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/


Therapeutic Management of Nonhospitalized Adults With COVID-19 https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/

ASPR

Pathway to Treatment: Patient with Confirmed COVID-19 Infection

- Treatment likely most beneficial to patients if given early in symptom progression
- EUA requires administration of treatment as soon as possible after confirmed positive test result and within 5 to 10 days of symptom onset*
- Strong **partnership and communication** between patients and HCP to get right treatment to right patients at right time
- Fast testing turnaround needed, to efficiently identify positive tests and schedule for treatment

Example of timeline which would fulfill EUA requirements




Early administration of treatment needs fast testing turn-around and patient scheduling

Planning required for "Test to Treat" models

*Please reference EUA factsheet for specific treatment guidelines including recommended treatment window



Minimize Leakages in the Patient Journey Around Awareness & Access





Meg Sullivan, MD, MPH Acting Chief Medical Officer, HHS ASPR

COVID-19 Test to Treat Strategy: Overall Goals

- Facilitate early diagnosis and rapid linkage to treatment for individuals with COVID-19 who are at high risk for complications.
- Prevent disease progression and transmission through early diagnosis and treatment of high-risk individuals, thereby reducing morbidity and mortality caused by COVID-19
- Reduce disparities in COVID-19 outcomes through equitable strategies that prioritize access to tests and reduce barriers to treatments for high-risk individuals disproportionately impacted by COVID-19

• Test to Treat efforts aim to address challenges with patients obtaining therapeutics, <u>including</u>:


- Consumer knowledge of "test to treat" guidance
- Access to tests upon symptom onset
- Access to healthcare provider (or treatment site for mAbs) within timeframe for treatment effectiveness
- Provider knowledge of and comfort level with prescribing therapeutics
- Equitable distribution of therapeutics, especially in the setting of limited supply
- Provider/consumer locating site with medication in-stock

COVID-19 Test to Treat Strategy: Overall Goals

- Increase COVID-19 test and treat health literacy.
- Ensure Access to Tests for early diagnosis, with a specific focus on high-risk individuals.
- Facilitate Rapid Linkage to Care after Positive Result, with a specific focus on high-risk individuals.
- Ensure Access to Therapeutics, with a focus on equitable distribution.

Increase COVID-19 Test to Treat Health Literacy

• Include Test to Treat language on testing websites



Updated Feb. 1, 2022 Languages

Print

CDC has updated <u>isolation and quarantine</u> recommendations for the public, and is revising the CDC website to reflect these changes. These recommendations do not apply to <u>healthcare personnel</u> and do not supersede state, local, tribal, or territorial laws, rules, and regulations.

Free At-Home COVID-19 Tests: Order 4 free tests now so you have them when you need them.

If you test positive for COVID-19 and have <u>one or more health</u> conditions that increase your risk of becoming very sick, <u>treatment may be available</u>. Contact a health professional right away after a positive test to determine if you may be eligible, even if your symptoms are mild right now. Don't delay: Treatment must be started within the first few days to be effective.

https://www.cdc.gov/coronavirus/2019-ncov/testing/selftesting.html



What if you test Positive?

A **positive** at-home test result means that the test found the virus, and you very likely have COVID-19.

If you test positive, follow the <u>latest</u> <u>CDC guidance for isolation</u> ☑.

If you test positive and have a weakened immune system or <u>other</u> <u>health conditions</u> 2, talk to a doctor as soon as possible about <u>available</u> <u>treatment options</u> 2.

What if you test Negative?

A **negative** at-home test result means that the test did not find the virus, and you may have a lower risk of spreading COVID-19 to others. Check your test kit's instructions for specific next steps. If you test negative, you should test again within a few days with at least 24 hours between tests.

If you test negative, follow the <u>latest CDC guidance for</u> <u>self-testing</u> ⊠.

https://www.covidtests.gov/

Increase COVID-19 Test to Treat Health Literacy

DON'T DELAY: TEST SOON AND TREAT EARLY

COVID-19



Contact your healthcare provider right away if your result is positive.





cdc.gov/coronavirus

https://www.cdc.gov/coronavirus/2019ncov/downloads/communication/printresources/Test-Soon-Treat-Early.pdf




Increase COVID-19 Test to Treat Health Literacy

J	AMA Network			
	JAMA Internal Medicine	Search All	Ŧ	Enter Search Term
	•	onsumers Interpret an e COVID-19 Self-test cal Trial		t on Re-
	Steven Woloshin, MD, MS ^{1,2} ; Barry Dewitt, PhD ³ Author Affiliations Article Information JAMA Intern Med. Published online January 31,			
		Interviews		
	Key Points			
	Food and Drug Administration or instruction	of at-home COVID-19 self-test kits when they ns developed with decision science principles, nmendations or quarantine unnecessarily?		-
	results of at-home self-tests by failing to co	360 adults in the US found that a substantial provider the implications of a high pretest probal cision science-based instructions may increased	oility of infect	tion and ignoring the fed-
		clinical trial indicate that people who use at-ho ssarily because they misinterpret the implication the harms from at-home self-test kits.		

Uncla<u>ssified</u>

Increase COVID-19 Test to Treat Health Literacy/Ensure Access to Therapeutics

 Amplify existing resources, and develop additional resource for linkages to therapeutics for healthcare providers



https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/



Weekly Stakeholder Engagements

- Office Call Sessions: HHS/ASPR Distribution and Administration of COVID-19 Therapeutics
 - Tuesdays (2:00-3:00PM ET) https://hhsasproea.zoomgov.com/j/1604329034?pwd=dGRwZTBETTJzWFliQW83TXZSOFVNQT09
- Stakeholder Call: Federal Retail Pharmacy Therapeutics Program (FRPTP) Participants
 - Every other Tuesday (12:00-12:30PM ET); Next meeting March 8
- Stakeholder Call: State and Territorial Health Officials
 - Wednesdays (2:00-3:00PM ET)
- Stakeholder Call: National Health Care and Medical Orgs and Associations
 - Wednesdays (3:15-4:15PM ET)

https://hhsasproea.zoomgov.com/j/1617766329?pwd=SEVPMzIQWDQyYWo2KzcxVU01THluQT09

- Health Partners Ordering Portal (HPOP) Office Hours
 - Thursdays (4:00-5:00PM ET) https://hhsasproea.zoomgov.com/j/1603047233?pwd=V3R4OG1LSDhUZ2I0Y0NhZkUxVlkxdz09
- Federal COVID-19 Response: COVID-19 Therapeutics Clinical Webinar
 - Every other Friday (12:00-1:00PM ET); Next meeting March 4

https://hhsasproea.zoomgov.com/j/1617536991?pwd=NjFMcnJOUENuSFhtRFFtaWltejYzZz09

Questions or need the Zoom link for identified engagements? Email us at COVID19Therapeutics@hhs.gov.

Increase COVID-19 Test to Treat Health Literacy/Ensure Access to Therapeutics

<i>⊰</i> ⊮- Health Resources	s & Services Admini	Explore 🕂				
	SA		Q			
Health Center	Program				f 🖸 🙆 🖂 Ƴ	
Program Requirements	Quality Improvement	Program Opportunities	Health Center Data	Federal Tort Claims Act	About the Health Center Program	

Home > Emergency Preparedness, Response, and Recovery Resources for Health Centers > HRSA Health Center COVID-19 Therapeutics Program

HRSA Health Center COVID-19 Therapeutics Program



View participating health centers.

The Biden-Harris Administration is committed to ensuring our nation's underserved communities and those disproportionately affected by



- Goal of Test to Treat: Facilitate early diagnosis and rapid linkage to treatment for individuals with COVID-19 who are at high risk for complications, thereby reducing morbidity and mortality caused by COVID-19 and reducing disparities in COVID-19 outcomes.
- Requirements for successful Test to Treat model for Oral Antivirals:
 - Awareness by patient and provider of current testing and treatment guidance and availability.
 - Rapid access to test and results after symptom onset.
 - Timely access to a healthcare provider for evaluation and prescription.*
 - Timely access to medication (within a few days after symptom onset.)

Test to Treat Initiative

- Promote and support a variety of existing and new pathways for increased public and provider awareness, rapid access to tests, and/or linkage to treatment, including:
 - Public education campaign and enhanced patient/consumer education and messaging
 - Provider outreach to increase knowledge of and comfort level with prescribing therapeutics
 - Ensuring access to and prepositioning tests in high priority settings & populations
 - Ensuring access to and prepositioning therapeutics in high priority settings and populations
 - HRSA-funded health centers
 - Working with states/territories to support efforts re: distribution to high priority locations
 - Prioritize other settings in which end-to-end test to treat model can be provided and/or disease burden is high
 - Ongoing efforts to increase supply of therapeutics
 - Exploring further opportunities for telehealth and other options for linkage to care and treatment

The Reliable Acquisition of Pharmaceuticals for Immediate Distribution (RAPID) Program for Long-Term Care Facilities

To facilitate early diagnosis and a rapid link to treatment options for high-risk individuals in long-term care facilities (LTCFs), HCORE is working on the RAPID initiative to increase access of oral antivirals (OAVs) to the long-term care community.

Guiding Principles

- RAPID would involve a separate federal cache that would not impact current partners allocations.
- Current data on OAVs shows only a ~62% utilization of Paxlovid and ~14% utilization of molnupiravir.
- Initially, this channel would utilize molnupiravir, which is in abundant supply, and potentially add Paxlovid when supply is not constrained.
- Aid states by identifying long-term care supporting pharmacies (LTCPs) within their jurisdictions.
- Identified LTCPs would have the ability to open order with guard rails, closely tied to utilization.
- Ensure maximum visibility by the states and jurisdictions on product supplies in LTCPs and LTCFs.
- Ensure equitable distribution of therapeutics.
- Provide an efficient and flexible logistical and distribution structure to meet the current and future demand for therapeutics when and where needed.



Panel Roundtable Discussion and Q&A



COVID19Therapeutics@HHS.gov

ASPR.HHS.gov



Contact ASPR TRACIE

